In the past 15 years integrin signalling has been profoundly implicated in cancer cell proliferation, survival and invasion 1 . Current knowledge implies that in cancer cells integrins, receptor tyrosine kinases (RTKs) and cytokine receptors constitute joint modules in which attachment to the extracellular matrix (ECM) confers positional control to the activated signalling pathways (BOX 1). This allows cells to respond to soluble growth factors, which thereby determine the nature and the extent of the response 1,2 . This control mainly relies on the recruitment of adaptor proteins that behave as molecular hubs for intracellular signalling and organize complex signalling networks in time and space [3] [4] [5] [6] . The biological effects that are regulated by integrin and RTK signalling adaptors are dependent on their expression levels and on their phosphorylation status, which determines their association with binding effectors.
although p130CAS is ubiquitously expressed, NEdd9 expression is confined to epithelial tissues 3, 4 . CASS4 and EFS are less abundant and specifically expressed in spleen and lung (CASS4) 7 , and T lymphocytes, thymus, brain and skeletal tissue (EFS) 8 , making their functions limited to certain contexts.
overexpression of Cas proteins contributes to the development of human cancer. p130CAS is necessary for transformation by several oncogenes, such as SRC and ERbb2 (also known as HER2) as well as the oncogenic fusion protein nucleophosmin (NPM1)-anaplastic lymphoma receptor tyrosine kinase (ALK) [9] [10] [11] . Recently, p130CAS has been shown to be required for KRAS, bRAF, PTEN and PIK3CA oncogene-dependent proliferation 12 . Nevertheless, investigation of its expression in biopsy samples of different human malignancies using immunohistochemistry is still limited to breast cancer and haematological malignancies (TABLE 1) . It has recently been reported that in human breast cancers overexpression of both ERBB2 and p130CAS is associated with increased proliferation, metastasis and poor prognosis 13, 14 (TABLE 1) . Consistently, double transgenic mice that overexpress both p130CAS and ERBB2 in the mammary gland show an accelerated onset of tumour formation, providing evidence that p130CAS and ERBB2 synergize in vivo to transform the mammary epithelium 13 (TABLE 2) .
Indeed, p130CAS silencing in ERbb2-transformed breast cancer cells is sufficient to inhibit tumour growth in vivo and correlates with the downregulation of proliferative and survival pathways, such as SRC and AKT activation, focal adhesion kinase (FAK) phosphorylation and cyclin d1 expression 11 . In oestrogen receptor (ER)-positive human breast tumours, overexpression of p130CAS correlates with intrinsic resistance to tamoxifen treatment in a large subset of human breast cancer samples [15] [16] [17] . The second member of the family, NEdd9, has been identified as a metastasis gene in melanoma and in head and neck squamous cell carcinoma (HNSCC). Indeed, NEdd9 expression is higher in human metastatic melanoma than in primary melanoma 18, 19 and invasive HNSCC 20 . A role in mammary tumorigenesis has also been proposed for NEdd9, the absence of which significantly impairs tumour formation that is induced by the polyomavirus middle T (PyMT) oncogene 21 (TABLE 2) .
overall, p130CAS and NEdd9 expression levels are crucial for the onset and progression of many aggressive cancers, highlighting their importance as unfavourable prognostic markers.
The Crk family. The Crk family consists of three members: CRKI, CRKII 22 , which are alternative transcripts of CRK, and CRK-like protein (CRKL) 23 (FIG. 1) . The Crk family SH2 domains can bind to various key signalling molecules, including p130CAS.
The Crk family has been shown to be overexpressed in lung adenocarcinoma 24 , human colon cancers 25 and malignant glioblastoma 26, 27 . High levels of CRK mRNA and protein expression correlate with increased tumour aggressiveness in the lung, contributing to poor prognosis and shorter survival 24 . It was recently shown that CRK is a key regulator of mammary gland tumorigenesis. A subset of mouse mammary tumour virus (MMTV)-CRK-transgenic mice develops focal mammary tumours with a latency of 15 months, suggesting a potential role for CRK in integrating signals for breast cancer progression in vivo 28 (TABLE 2) .
The IPP complex. The IPP adaptor complex comprises ILK, PINCH1 (also known as LIMS1) or PINCH2 (also known as LIMS2), and parvin-α, parvin-β or parvin-γ (FIG. 1) .
The expression of ILK has been analysed in a large number of human malignancies [29] [30] [31] and is often found to be increased and associated with tumour progression and shortened survival (TABLE 1) . Increased ILK expression has been associated with more differentiated areas of malignant gastrointestinal, renal, neural and bone marrow tumours, suggesting that ILK might also be an indicator of differentiation 29, 32 . Evidence for the role of ILK in breast cancer development derives from the generation of transgenic mice that overexpress ILK in the mammary gland epithelium, and ILK overexpression leads to mammary gland hyperplasia and breast tumours of diverse phenotypes 33 . Moreover, targeted ablation of ILK in the mammary gland provides a direct demonstration that this molecule is required in the initiation phase of ERBB2-induced tumours, resulting in delayed tumour growth in vivo and a profound block of invasive properties in vitro owing to the induction of apoptosis 34 . Recently, it has been described that transgenic MMTV-ILK mice have lobuloalveolar hyperplasia and MMTV-ILK; MMTV-Wnt1 mice show significant acceleration in mammary tumour incidence and growth 35 (TABLE 2) .
At a glance
• In cancer cells, integrin and growth factor receptor crosstalk leads to the recruitment of integrin signalling adaptors to assemble intracellular signalling platforms that result in cellular transformation and the control of migration and invasion. The biological effects that are regulated by integrin adaptors are dependent on their expression levels and on their phosphorylation status, which determine the association with binding effectors.
• p130 Crk-associated substrate (p130CAS; also known as BCAR1), neural precursor cell expressed, developmentally down-regulated 9 (Nedd9; also known as HeF1), CRK, the integrin-linked kinase (ILK)-pinch-parvin (IPP) complex and p140 Cas-associated protein (p140CAP; also known as SRCIN1) integrin adaptors have a profound influence on all aspects of cancer progression, including initiation, progression and metastasis. Transgenic and xenograft animal models support the crucial role of these integrin adaptors in tumorigenesis.
• In several human tumours, high expression of p130CAS, Nedd9, CRK, ILK, PINCH1 and PINCH2 correlates with increased disease progression, and the levels of parvin-β and p140CAP proteins are inversely correlated with malignancy. Current knowledge also implicates integrin adaptors in acquired resistance to cancer treatment.
• In cancer cells, at the molecular level, these adaptors regulate signalling pathways that are required for the control of cell proliferation, survival and for actin cytoskeleton organization and extracellular matrix degradation. These events are fundamental for transformation and cancer progression, highlighting the integrin adaptors as key players in the onset of tumorigenesis.
• Targeting integrin adaptors by modulating their expression levels or their activity in different types of cancer has been proven to be effective for interfering with malignancy, making the integrin adaptors suitable targets for cancer therapy.
G3 index
In the classification of human breast cancer, grade 3 (G3) indicates that the cancer has spread to lymph nodes, regardless of its size.
Less is known about the expression of the other members of the IPP complex in cancer tissues. PARvb (which encodes parvin-β) mRNA and protein levels are markedly downregulated in several advanced breast tumours 36 and its expression is inversely correlated with ILK protein and kinase activity levels, suggesting that the downregulation of parvin-β expression upregulates ILK activity in human tumours (TABLE 1) . PINCH1 and PINCH2 expression in samples of breast, prostate, lung, colon and skin carcinomas was found to be upregulated in tumour-associated stromal cells, especially at the tumour-invasive edges 37 . In particular, in a large series of colon cancers, strong PINCH1 and PINCH2 stromal expression was associated with lower patient survival, suggesting that these proteins are independent prognostic indicators of colon cancer 38 (TABLE 1) .
The Cap family. The Cap family consists of two members, p140CAP and sickle-tail (SKT). p140CAP has been shown to downregulate integrin-and growth factordependent signalling 39, 40 . p140CAP 41, 42 and SKT 43, 44 are multisite docking proteins, which are characterized by conserved sequence motifs that can associate with multiple effectors (FIG. 1) .
p140CAP is mainly expressed in the brain, testes and epithelial-rich tissues such as the mammary glands, lungs, colon and kidneys 41, 45, 46 , and is phosphorylated on serine and tyrosine residues 41, 46, 47 ; the relevance of p140CAP phosphorylation in downstream signalling needs to be assessed. p140CAP functions as a tumour suppressor protein, as its silencing favours anchorage-independent growth and in vivo tumour growth 39, 40 . Although few data are available on p140CAP expression in human tumours, a recent screen of mammary breast cancers revealed that p140CAP is not expressed in 70% of tumour specimens that are characterized by G3 index, node positivity and a high proliferation index, which indicates an inverse correlation of p140CAP expression with malignancy 39 . By contrast, an additional report shows that SRCIN1 (which encodes p140CAP) mRNA expression positively correlates with unfavourable prognostic factors in breast cancer 48 . These apparently conflicting results suggest the existence of dNA mutations or chromosome rearrangements that affect protein translation, which result in reduced levels of p140CAP expression in tumours. Indeed, SRCIN1 is located on human chromosome 17q12 and its flanking regions contain several genes that are involved in tumour initiation and progression, such as ERbb2 (17q12), bRCA1 (17q21), retinoic acid receptor-α (RARA; 17q21) and signal transducer and activator of transcription 3 (STAT3; 17q21), which are often translocated as fusion partners of the mixed-lineage leukaemia (MLL) gene in haematological malignancies, and are also amplified in human tumours, suggesting that SRCIN1 might also be subjected to such chromosome rearrangements 49 . Together, the data summarized above suggest that the expression of integrin adaptors is deregulated in various human cancers. Although the precise molecular mechanisms that cause this altered expression are currently not understood, extensive work on cancer cell models show that these scaffold proteins are involved in cancer initiation, progression and metastasis formation. Therefore, their involvement in these three fundamental steps of tumorigenesis makes them attractive targets for prognostic and therapeutic purposes.
The Cas family in cancer biology
The Cas family represents a nodal signalling platform on which integrin and growth factor receptor signalling converge. As a consequence, this family is implicated in key events in cancer cell biology such as the acquisition of pro-survival and pro-invasive phenotypes (FIG. 2) . The molecular mechanisms underlying these events are discussed below.
Migration and invasion.
In cancer progression, cellcell detachment from the primary tumour and the acquisition of a motile phenotype are required for cells to become invasive and colonize distant organs to generate metastasis. Growing evidence shows that Cas family proteins are major players in migration, invasion and metastasis formation, mainly by undergoing phosphorylation, activating Rho family GTPases and inducing matrix metalloproteinase (MMP) gene expression.
Tyrosine phosphorylation of the p130CAS substrate domain (Sd) mainly by SRC and FAK 50 allows the assembly of the p130CAS-CRK-dedicator of cytokinesis 1 (doCK1; also known as doCK180) complex and efficient localized activation of the small GTPase RAC1 at the cell membrane. These events induce cell
Box 1 | Integrin signalling and cancer
Integrins are enzymatically inactive receptors, which, on binding to the extracellular matrix (eCM), undergo a conformational change that consequently connects extracellular signals to intracellular adaptor molecules that elicit signal transduction, which is known as 'outside-in' signalling. Integrins have been profoundly implicated in cancer cell proliferation, survival and invasion 1, 135, 136 . In cancer, integrins are generally aberrantly expressed, rather than present as dominant genetic variants. This aberrant integrin expression can sustain tumours by activating signalling pathways that lead to the inhibition of apoptosis and induction of cell proliferation, eCM remodelling, migration and angiogenesis. Integrins are also expressed on tumour-associated cells, such as stromal fibroblasts, endothelial cells, perivascular cells, bone marrow-derived cells and platelets. The contribution of these cells to cancer progression is highly controlled by integrin signalling 137 . Integrins are also required for metastatic dissemination, including tumour cell migration, invasion and the colonization of target tissues 138, 139 . Integrin-stimulated pathways are also implicated in the induction of resistance to chemotherapy and ionizing radiation in vitro 140 . One mechanism through which integrins are involved in tumour initiation and progression consists of the cooperation between integrins, receptor tyrosine kinases (RTKs) and cytokine receptors. Integrins are required for full tyrosine phosphorylation of the receptors, their binding to signalling molecules and the activation of downstream pathways. These signalling cascades generate crucial functional platforms that are important for tumorigenesis, angiogenesis and metastasis 1, 2, 141, 142 . New findings indicate that integrins exert control over the endosomal trafficking of other RTKs, such as epidermal growth factor receptor (eGFR), to regulate cell migration and invasion 143 . Moreover, enhanced integrin-eGFR trafficking is a key mechanism by which a mutant form of the tumour suppressor protein p53 can trigger metastasis of cancer cells 144 . Therefore, cancer cells are strictly dependent on integrin signalling, making the unravelling of the role and functions of integrin signalling adaptors of crucial importance to tumour cell biology. [51] [52] [53] . uncoupling of p130CAS-CRK negatively regulates cell migration. Indeed, the non-receptor tyrosine kinase ABL1 phosphorylates CRKII on tyrosine 221 (FIG. 1) , inducing intramolecular folding that prevents binding of the carboxy-terminal SH2 domain of CRKII to the phosphorylated Sd of p130CAS, leading to decreased cell movement 54, 55 . p130CAS has also emerged as a pro-invasive molecule. To regulate invasion p130CAS associates with the Zyxin family members (zyxin, ajuba (JuB) and thyroid hormone receptor interactor 6 (TRIP6)) [56] [57] [58] and the transcription factor zinc finger protein 384 (ZNF384; also known as CIZ and NMP4) 56 . These interactions lead to the transcription of MMP genes that are required for the invasive programme 59 .
In the context of SRC transformation, SRC requires p130CAS for the organization of actin into podosomes, the activation of MMP2 and the formation of lung metastases in vivo 60 . Moreover, bosutinib, a novel SRC kinase inhibitor, has been reported to prevent breast cancer cell migration and invasion by inhibiting the SRC-FAK-p130CAS signalling pathway 61 . In ERBB2-transformed cells, p130CAS overexpression confers invasive properties in three-dimensional cultures, sustaining and strengthening PI3K-AKT and ERK1 (also known as MAPK3)-ERK2 (also known as MAPK1)-ribosomal protein S6 kinase (p70S6K; also known as S6K1) signalling downstream of ERBB2, which leads to RAC1 activation and MMP9 secretion 11 , respectively 14 . Consistently, p130CAS silencing in ERBB2-dependent breast carcinoma impairs migration and invasion in vitro, as well as the formation of lung metastases in vivo 11 . It has recently been proposed that ECM stiffness modifies the context of signalling and promotes the invasion of oncogene-transformed pre-malignant mammary cells 62 , and that integrins are mechanosensors for matrix and tissue rigidity 63 . Interestingly, p130CAS has been described as a major mechanotransduction protein, which undergoes phosphorylation on force-mediated conformational changes 64 , which senses fibronectin, but not collagen, rigidity . These data suggest that p130CAS might strenghten the intracellular signalling cascades that are activated by the ECM stiffness that is caused by the presence of a tumour.
The role of NEdd9 as a pro-migratory protein has been determined on the basis of its ability to activate RAC1 in highly metastatic melanomas, by forming a complex with doCK3, which is a RAC1 guanine nucleotide exchange factor (GEF). RAC1 activation results in a switching from amoeboid movement to mesenchymal movement, the suppression of Rho GTPase activation and the loss of actomyosin contractility and motility 66 . Also in glioblastoma cells, NEdd9 is pro-migratory on platelet-derived growth factor (PdGF) stimulation 67 . opposite effects have been reported in a recent small interfering RNA (siRNA) screen of human mammary epithelial cells. In this report, NEdd9 was classified as anti-migratory, probably through its ability to polarize the microtubule network, suggesting a role for NEdd9 in microtubule-organizing centre (MToC) polarization 68 . Further investigations are required to reconcile these opposing data, which might be explained by the different cellular context that was analysed. domain, which binds the phosphorylated Sd of p130CAS, and of two SH3 domains. The first SH3 domain interacts with Rap guanine nucleotide exchange factor 1 (RAPGEF1; also known as C3G), dedicator of cytokinesis 1 (dOCK1; also known as dOCK180) and ABL1. A crucial tyrosine residue (Y221) is phosphorylated by ARG (also known as ABL2) and ABL1. c | The integrin-linked kinase (ILK)-pinch-parvin (IPP) complex is shown. ILK consists of an N terminal ankyrin repeat (ANK) domain, a plekstrin homology (PH) domain and a C terminal kinase domain. ILK binds to the LIM1 domain of pinch and to the second charged amino acid-rich domain (CH2) of parvin. The main interactors of the IPP complex are indicated. d | p140 Cas-associated protein (p140CAP; also known as SRCIN1) consists of an N terminal tyrosine-rich region (TYR RICH), an actin-binding domain (ABd), a proline-rich domain (Pro1), a coil-coiled region (C1-C2), two domains rich in charged amino acids (CH1 and CH2) and a C terminal proline-rich domain (Pro2). SRC, p130CAS, MAPRE3 (also known as EB3) and vinexin bind to the Pro2 domain of p140CAP. The binding region of c-src kinase (CSK) has yet to be defined. BCAR3, breast cancer anti-oestrogen resistance 3 (also known as ANd34); FAK, focal adhesion kinase; FERMT2, fermitin family member 2 (also known as kindlin 2); FRNK, focal adhesion kinase-related non-kinase; GAB1, GRB2-associated binding protein 1; ILKAP, integrin-linked kinase-associated serine/threonine phosphatase 2C; NCK, NCK adaptor protein; NEdd9, neural precursor cell expressed, developmentally down-regulated 9 (also known as HEF1); PTPN12, protein tyrosine phosphatase, non-receptor type 12 (also known as PTP-PEST); PXN, paxillin; PYK2, proline-rich tyrosine kinase 2 (also known as FAK2); SHIP2, SH2 domain-containing inositol-5′-phosphatase 2; Tβ4, thymosin-β4; ZNF384, zinc finger protein 384 (also known as CIZ).
Podosome
A type of ECM contact that is different from focal complexes and focal adhesions. It is built around an actin filament core, surrounded by a ring structure of integrin adhesive complexes.
Amoeboid movement
This movement is characterized by high speeds, a lack of stable polarity and an amorphous cell shape, and it is frequently exhibited by cancer cells. It does not require stable integrin-dependent adhesion for traction but depends on RHOA to increase actomyosin contractility and allow invasion in the absence of extracellular proteolysis.
Mesenchymal movement
The movement of cells with elongated morphology and a front-back polarity, with traction generated through integrin-dependent adhesion. This type of motility requires extracellular proteolysis for cell invasion and is thought to depend on RAC1.
Collective motility
The migration of cells as a cohesive group, a hallmark of tissue remodelling during wound repair and cancer invasion. It is characterized by cells moving as sheets, strands, clusters or ducts rather than individually.
TGFβ signalling and cancer progression. A role for p130CAS and NEdd9 in transforming growth factor-β (TGFβ) signalling has recently been proposed. This regulatory cytokine exerts tumour-suppressive effects that cancer cells must elude for malignant evolution. Paradoxically, cancer cells elicit mechanisms that subvert the tumour suppressing functions of TGFβ, and thus confer oncogenic and metastatic activities on this multifunctional cytokine 69, 70 . In epithelial cells, integrin β1 suppresses apoptosis and growth inhibition that is induced by TGFβ 71 . In this context p130CAS has been shown to be a crucial player by binding to SMAd3 and preventing its phosphorylation by the TGFβ receptor. As a consequence, the transcription of the cyclin-dependent kinase inhibitors p15 (also known as INK4B) and p21 (also known as CdKN1A) is inhibited, resulting in cell cycle progression 72 . Recently, it has been reported that p130CAS overexpression in mammary epithelial cells (MECs) shifts TGFβ signalling from SMAd2 and SMAd3 phosphorylation to p38 MAPK activation, rendering MECs resistant to TGFβ-induced growth arrest and enhancing their metastatic potential 73 . Notably, NEdd9 was found to be a new transcriptional target of TGFβ signalling in highly metastatic mammary adenocarcinoma cells that switch from collective motility to single cell motility, and its silencing results in inhibition of amoeboid motility in response to TGFβ 74 . overall, the Cas family can function as a molecular rheostat that switches the tumour suppressor function of TGFβ to a pro-metastatic role during breast cancer progression.
Epithelial-mesenchymal transition (EMT) is a known mechanism through which epithelial cells lose their epithelial characteristics and acquire a mesenchymal phenotype to become migratory and invasive 75 . ECM molecules such as collagen I have been shown to induce EMT in transformed epithelial cells. Highly invasive pancreatic cancer cells bind to collagen I through integrin β1 and discoidin receptors, and upregulate N-cadherin on the cell surface, which leads to increased cell motility 76, 77 . In this model, p130CAS has a crucial role in collagen I-mediated cell movement, as well as in the upregulation of N-cadherin, as it functions as a scaffold, integrating integrin β1 and discoidin receptor signalling in the plasma membrane 78 . ER, oestrogen receptor; HNSCC, head and neck squamous cell carcinoma; ILK, integrin-linked kinase; NEdd9, neural precursor cell expressed, developmentally down-regulated 9 (also known as HEF1); p130CAS, p130 Crk-associated substrate (also known as BCAR1); p140CAP, p140 Cas-associated protein (also known as SRCIN1).
These findings suggest that the Cas family members are potential modulators of ECM-dependent EMT for the acquisition of aggressive cancer properties.
Apoptosis.
Cell death by apoptosis is a protective mechanism for maintaining cell homeostasis in the adult organism, and its inhibition contributes to transformation. p130CAS and NEdd9 are both targets of apoptotic pathways, undergoing proteolytic cleavage and generating fragments that directly participate in the disruption of focal adhesions and cell death. Caspase 3-dependent cleavage of p130CAS releases a 31 kda fragment that has pro-apoptotic activities. This fragment translocates to the nucleus and heterodimerizes with the transcription factors E2A or E47, thereby repressing CdKN1A (which encodes p21) transcription, promoting loss of focal adhesions, and inducing cell rounding and cell death 79, 80 . Similarly, the proteolytic cleavage of NEdd9 by caspase 3 and/or caspase 7 releases a C terminal p28 fragment that, in MCF-7 and HeLa cells, induces focal adhesion disassembly, cell detachment and apoptosis 81 , in a mechanism similar to that described for p130CAS, suggesting that NEdd9 might also bind E2A and therefore cause the transcriptional repression of CdKN1A.
In tumours, p130CAS cleavage might represent a mechanism for interfering with cancer cell survival. It has been observed that silencing of the protein tyrosine phosphatase regenerating liver (PRL3; also known as PTP4A3) leads to the induction of p130CAS cleavage and anoikis, thus preventing anchorage-independent growth of colon carcinoma cell lines 82 . Interestingly, p130CAS expression is reduced on Prl family knockdown in colon and lung cancer cells 82, 83 , indicating that these phosphatases are crucial regulators of p130CAS protein levels. In addition, p130CAS cleavage may result from the overexpression of the chemokine CXCL12 (also known as SdF1) 84 and also from the inhibition of cyclooxygenase 2 (CoX2; also known as PGH2) activity, which is a key enzyme in prostaglandin synthesis that promotes tumour progression and angiogenesis 85 . The treatment of colon cancer cells with the CoX2 inhibitor celecoxib induces proteolysis of p130CAS and nuclear translocation of the 31 kda fragment, which leads to apoptosis 86 . Moreover, in a panel of human acute myeloid leukaemia cell lines, the antitumour effect observed on treatment with celecoxib is due to the inhibition of p130CAS signalling leading to apoptosis 87 .
In conclusion, members of the Cas family function as crucial scaffolds to modulate the survival of various cancer cells. Therefore, interfering with the pro-survival properties of the Cas adaptors might represent an important mechanism for triggering cancer cell death.
The Crk family in cancer biology
The ability of the Crk family of adaptor proteins to induce cell transformation, migration and invasion mainly relies on the p130CAS-NEdd9 and the FAK-SRC pathways, making CRK an attractive target owing to its central integrative downstream role in signalling by these molecules 5 . CRK-mediated transformation induces increased p130CAS-associated activity of Src family kinases (SFKs) 88 , FAK phosphorylation by SFKs and the recruitment of PI3K to FAK 89, 90 . overexpression of CRK in tumour cells leads to an increase in p130CAS tyrosine phosphorylation and the activation of an intracellular feedback loop that further increases CRK activity and induces motility and the aggressive potential of cancer cells. Therefore, Crk family proteins are not simply conduits for intracellular signal transduction but can also control the amplitude of signalling.
Migration and invasion.
In addition to the role of CRK in Cas family-mediated migration and invasion, in synovial sarcoma cell lines CRK has a crucial role in the response to hepatocyte growth factor (HGF) by activating RAC1 through the sustained binding of CRK to GRB2-associated binding protein 1 (GAB1), a docking protein that recruits CRK on phosphory lation of the HGF receptor MET. Remarkably, CRK silencing suppresses tumour formation in human synovial sarcoma cell xenografts and invasive growth in vivo 91, 92 . 93 . what regulates the assembly of specific CRK complexes in different tumour cells is still unknown.
The IPP complex and cancer biology
The IPP complex has emerged as an essential constituent of integrin-containing adhesion sites and it can function both as a structural module that connects integrins to the actin cytoskeleton and as a signalling platform that modulates various cellular processes (FIG. 3) . The expression of members of the IPP complex in physiological conditions controls normal development and tissue homeostasis. Conversely, correlative studies of the three members of the IPP complex in cancer biology are still lacking and only the single components have been analysed 6, 94 . ILK is a central component for the assembly of the IPP complex, and it contributes both its kinase activity and its adaptor properties [95] [96] [97] [98] . Indeed, ILK adaptor function is required for binding to parvin-α and parvin-γ, but although parvin-α inhibits ILK kinase activity 99 , parvin-γ association results in the induction of ILK kinase activity 98 . Therefore, the degree of ILK kinase activity within the IPP complex might be modulated by its association with different binding partners depending on specific cellular cues. The regulation of the kinase activity by the assembly of different complexes might also explain the observed role of ILK as an oncogene or a tumour suppressor, as outlined below. Crk-associated substrate (p130CAS; also known as BCAR1) and neural precursor cell expressed, developmentally down-regulated 9 (NEdd9; also known as HEF1), mainly through the activation of the kinases SRC and focal adhesion kinase (FAK), which phosphorylate p130CAS and NEdd9 and form a Cas-SRC-FAK complex. Tyrosine phosphorylated Cas proteins recruit the adaptor CRK, which in turn binds to several guanine nucleotide exchange factors (GEFs) that switch small GTPases from a GdP-bound inactive state to a GTP-bound active state, which promotes cell migration. On the one hand, growth factor receptor-bound protein 2 (GRB2) binding leads to ERK1-ERK2-mediated cell transformation. On the other hand, PI3K-AKT activation sustains cell survival. p130CAS also regulates the invasive programme through its interaction with the transcription factor zinc finger protein 384 (ZNF384; also known as CIZ) that transactivates promoters for matrix metalloproteinases (MMPs). b | In transforming growth factor-β (TGFβ) signalling, p130CAS mediates integrin-dependent suppression of TGFβ-induced apoptosis and growth inhibition. p130CAS binding to SMAd3 reduces TGFβ-dependent SMAd3 phosphorylation leading to growth arrest. p130CAS overexpression increases TGFβ coupling to p38 MAPK thus inhibiting TGFβ-induced growth arrest and enhancing the metastatic potential. NEdd9 has been reported as a transcriptional target of TGFβ signalling and enhances cell motility in response to TGFβ. c | On pro-apoptotic stimuli, Cas proteins undergo dephosphorylation by protein tyrosine phosphatase, non-receptor type 12 (PTPN12; also known as PTP-PEST) and PTPN1 phosphatases, resulting in the disassembly of Cas-dependent signalling complexes. Moreover, p130CAS and NEdd9 dephosphorylation favours caspase-dependent cleavage with the production of smaller fragments that bind to E2A and enter the nucleus, contributing to cell death by transcriptional repression of CDKN1A (which encodes p21). NEdd9 association with aurora kinase leads to cell cycle arrest owing to inhibition of cytokinesis that is induced by centrosome amplification and multipolar spindles. BCAR3, breast cancer anti-oestrogen resistance 3 (also known as ANd34); CXCL12, C-X-C motif chemokine 12 (also known as SdF1); dOCK, dedicator of cytokinesis; JNK, JUN N-terminal kinase; JUB, ajuba; TRIP6, thyroid hormone receptor interactor 6; ZYX, zyxin. Nature Reviews | Cancer ILK as on oncogene. ILK has been described as being involved in all aspects of cancer cell progression. ILK overexpression in epithelial cells leads to cell transformation, invasion, and the acquisition of survival and mesenchymal properties, supporting a role for ILK as an oncogene 31 . In mammary epithelial cells, ILK overexpression triggers EMT, which is characterized by the loss of E-cadherin and β-catenin in adherens junctions and β-catenin accumulation in the nucleus, leading to increased synthesis and deposition of fibronectin, further supporting ILK-dependent EMT 100 . ILK-transformed cells undergoing EMT are characterized by increased migration through the activation of the small GTPases RAC1 and cell division cycle 42 (CdC42), the activity of which is inhibited by ILK knockdown or suppression of its kinase activity 101 . It has also been observed that ILK overexpression in intestinal and mammary epithelial cells leads to a highly invasive phenotype resulting from MMP9 upregulation and activation 102 . Recently, a new function of ILK in the regulation of the microtubule cytoskeleton and mitotic spindle organization has been proposed 103 . Inhibition of ILK expression or activity impairs centrosome clustering in several breast and prostate cancer cell lines with centrosome amplification and induces mitotic arrest and cell death, demonstrating that inhibiting ILK offers a selective means of targeting cancer cells 104 .
ILK as a tumour suppressor. ILK has also been described as a tumour suppressor in cancer cells. For example, ILK expression levels are higher in MCF10A breast epithelial cells than in breast carcinoma cell lines, suggesting that ILK is lost during breast epithelial cell transformation 105, 106 . A rationale for explaining the oncogenic and tumour suppressing functions of ILK in tumour models has been recently established in aggressive paediatric rhabdomyosarcoma (RMS) tumours 107 . RMS tumours can be classified according to either embryonic (ERMS) or alveolar (ARMS) histology 108 . on the one hand, in vivo and in vitro studies indicate that in ERMS, endogenous ILK suppresses phosphorylation and therefore the activation of JuN N-terminal kinase 1 (JNK1; also known as MAPK8)-JuN signalling, reducing growth and inducing apoptosis. on the other hand, in ARMS, endogenous ILK induces JNK1 phosphorylation, resulting in enhanced growth. Therefore, this work might provide mechanistic insights into the role of ILK in RMS, as well as in other tumours, suggesting that patients should be stratified on the basis of ILK activity and JNK1 expression, in order to determine which patients might benefit from ILK inhibition as a form of targeted antitumour therapy 107 .
Parvin and pinch in cancer biology. Although parvin-α has been shown to promote anti-apoptotic signalling as a downstream element in ILK signalling 95, 109 , parvin-β functions as a tumour suppressor by inhibiting ILK signalling. Consistently, in breast cancer cells, PARvb mRNA and protein levels are markedly downregulated in several advanced tumours, and also in certain cancer cell lines, together with increases in ILK protein expression and kinase activity 36 . High levels of parvin-β correlate with increased cell adhesion, prevent anchorage-independent growth 36 and attenuate tumour growth in nude mice 110 . This tumour-suppressive role of parvin-β is consistent with deletions observed in the PARvb locus (22q13.21) in some colon and breast cancer cells 111 . Several lines of evidence have implicated PINCH1 and PINCH2 as suppressors of apoptosis. For example, in vitro inhibition of PINCH1 expression in HeLa cells and fibrosarcoma, breast, prostate, hepatocellular, lung and colon carcinomas leads to apoptosis 109, 112 . In vivo, knock out of Lims1 (which encodes PINCH1) in embryonic neural crest cells caused enhanced apoptosis 113 .
The Cap family in cancer biology
The major function of the p140CAP adaptor in tumour cells is to regulate SRC kinase activation 39, 40 . In particular, on cell-ECM adhesion or epidermal growth factor (EGF) stimulation of breast cancer cells, p140CAP activates c-src tyrosine kinase (CSK) 40 , which causes the closure of SRC in an inactive conformation by phosphorylating the inhibitory tyrosine on the C terminal domain of SRC 114 (FIG. 4a) . Therefore, p140CAP represents a new potent regulator of the proto-oncogene SRC that is able to shift the balance from active to inactive SRC. Consequently, integrin signalling that is dependent on SRC, such as tyrosine phosphorylation of FAK, and p130CAS and RAC1 activation, is impaired in cells expressing high levels of p140CAP 40 . 
Actin stress fibres
Self-assembling, structural components of the cytoskeleton that typically appear as long, thick actin bundles that span across the cell body and lie along the ventral surface. By binding to myosin, they produce traction forces and resting tension.
Cortical actin
A concentrated layer of actin filaments that lie longitudinally and roughly parallel to each other just beneath the plasma membrane.
In tumour cells p140CAP also regulates E-cadherindependent cell-cell adhesion. p140CAP regulates cellcell contact dynamics by increasing the amount of immobilized E-cadherin at the cell surface, thereby regulating the strength of cell-cell adhesion. This mechanism also depends on the inhibition of SRC kinase activity 39 . E-cadherin is known to inhibit EGF receptor (EGFR) signalling, either by interaction through the extracellular domains or by a β-catenin-dependent mechanism [115] [116] [117] . Indeed EGFR, Ras and ERK1-ERK2-MAPK activities are profoundly impaired when p140CAP is overexpressed, and enhanced when it is silenced 39 . p140CAP also regulates the Ras pathway through an additional unknown mechanism 39 . Therefore, in cancer cells, p140CAP regulates EGFR signalling through a dual mechanism, which involves E-cadherin-dependent inactivation of EGFR and Ras-dependent inhibition of ERK1-ERK2-MAPK activity.
For the second member of the family, SKT, one report in prostate cancer cells shows that KIAA1217 (which encodes SKT) expression is repressed by the androgen receptor, suggesting a potential role for SKT as a tumour suppressor, the loss of which may contribute to prostate carcinoma 118 .
Migration and invasion. p140CAP decreases the ability of breast cancer cells to spread on ECM proteins and to migrate and invade in in vitro assays. Consistently, p140CAP silencing accelerates the early phases of cell spreading on ECM, induces a fibroblastic-like morphology, and increases motility and invasion 40 . In addition, p140CAP specifically interferes with the ability of both breast and colon cancer cells to scatter from a compact colony in response to EGF 39 . The mechanism by which p140CAP interferes with cell scattering is based on the ability of p140CAP to immobilize E-cadherin at the cell membrane, as described above.
Actin cytoskeleton remodelling is a crucial requirement for cell scattering and motility. p140CAP has been shown to co-localize with actin stress fibres and cortical actin and to associate with proteins that are involved in actin cytoskeleton dynamics, such as p130CAS, SRC, vinexin and cortactin 41, 42, 119 . These findings, along with the presence of a putative actin-binding domain in p140CAP (FIG. 1) , suggest that this adaptor could be both directly and indirectly involved in actin filament assembly. whether other p140CAP-binding proteins are also involved in regulating actin cytoskeleton organization and cell motility remains to be investigated.
Proliferation. In addition to cell motility and invasion, the ability of p140CAP to regulate SRC and Ras pathways also profoundly affects cell proliferation. Increased expression of p140CAP in both breast and colon cancer cells inhibits proliferation in vitro, but does not affect cell survival 39, 40 . Interestingly, in breast cancer cells, p140CAP Crk-associated substrate (p130CAS; also known as BCAR1) tyrosine phosphorylation. Consequently, in cells expressing high levels of p140CAP the association between SRC and FAK is impaired on integrin-mediated adhesion. p130CAS phosphorylation leads to the assembly of a p130CAS-CRK signalling complex that drives RAC1 activation. Consistently, increased levels of p140CAP severely impair integrin-dependent RAC1 activity, and its downregulation induces sustained RAC1 activation. Moreover, by inactivating SRC, p140CAP also regulates the epidermal growth factor receptor (EGFR) pathway through E-cadherin-dependent inactivation of EGFR signalling. p140CAP functionally interacts with E-cadherin and EGFR at the cell membrane, immobilizes E-cadherin at the cell membrane and increases the interaction between E-cadherin and EGFR. As an alternative mechanism, p140CAP also impairs the Ras pathway.
expression controls anchorage-independent growth, probably by inhibiting downstream integrin signalling, such as SRC and RAC1 activation 40 . Moreover, in breast and colon cancer cell xenografts high levels of p140CAP impair tumour formation 39, 40 . Consistently, xenografts of carcinoma cells in which p140CAP is silenced dramatically increases tumour formation in vivo 39, 40 . Strikingly, p140CAP knockdown is sufficient for the growth of oestrogen-dependent MCF7 breast cancer cells in vivo, even in the absence of oestrogen pellets (a condition in which control cells are unable to grow). These findings also raise the possibility that p140CAP might regulate ER signalling, contributing to breast cancer resistance to hormonal therapies. In conclusion, p140CAP functions as a tumour suppressor protein in breast and colon cancer cells, with a broad effect on cell proliferation and tumour growth.
Clinical implications
Growing evidence supports a central role for p130CAS in acquired resistance to breast cancer therapy. In ER-positive breast cancer cells, p130CAS enhances oestrogen-dependent cell cycle progression by associating with ERα (also known as ESR1), SRC and the p85a subunit of PI3K 120 . bCAR1, which encodes p130CAS, is upregulated in breast tumours that are resistant to tamoxifen 121, 122 . Consistently, the overexpression of p130CAS in breast cancer cells induces proliferative signals that are not sensitive to treatment with either tamoxifen or the ER antagonist fulvestrant 121, 123 . Although it has been reported that a possible mechanism through which p130CAS induces tamoxifen resistance is by its binding to BCAR3 (also known as ANd34), a putative GEF for the RALA, Rap and RRAS GTPases 124 , the exact mechanism by which p130CAS and BCAR3 induce anti-oestrogen resistance remains unclear. In addition, it has been suggested that both serine and tyrosine phosphorylation of p130CAS are required for mediating oestrogen resistance 125, 126 . Recently, high levels of p130CAS in human breast cancer have also been associated with resistance to the cytotoxic agent doxorubicin. In particular, p130CAS-dependent SRC, AKT and ERK1-ERK2-MAPK activation and inhibition of apoptosis are thought to be crucial for conferring resistance to doxorubicin 127 . Although NEdd9 has highly conserved structural features with p130CAS, NEdd9 does not correlate with oestrogen resistance in breast cancer 126 . However, NEdd9 is overexpressed in imatinib-resistant gastrointestinal stromal tumour cells 128 , suggesting that overexpression of a specific Cas family adaptor is selective for acquired resistance to therapy in different cancer subtypes. Therefore, p130CAS and NEdd9 might confer resistance to cancer therapy by clustering and simultaneously amplifying several signalling pathways that are involved in cell proliferation and survival, thus rendering cancer therapy ineffective. It is also possible that the other integrin adaptors might mediate resistance to therapy through similar mechanisms.
The involvement of integrin adaptors in tumour initiation and progression and the association with acquired resistance make them suitable targets for cancer therapy. Strategies for targeting these adaptors could be a novel and intriguing approach to interfere with tumorigenesis. Silencing of p130CAS, NEdd9, CRK and ILK has provided new insights into the therapeutic use of these adaptor molecules. Interestingly, injection of bCAR1-specific siRNAs into the mammary gland of transgenic mice harbouring ERBB2-dependent spontaneous adenocarcinoma was sufficient to inhibit ERBB2 signalling and to reduce tumour initiation 11 . This is the first example of a preclinical study using bCAR1 siRNA in the treatment of ERBB2-dependent mammary tumours and indicates that p130CAS might be a potential therapeutic target for ERBB2-dependent tumours.
There is now considerable evidence that ILK can be successfully targeted to inhibit tumour progression in clinically relevant models of cancer. The use of RNA interference and antisense oligonucleotides to downregulate ILK expression, and small-molecule inhibitors to abrogate its kinase activity, has been shown to reverse ILK oncogenic effects in various cancers. Indeed, inhibition of either ILK expression or its activity results in decreased cell migration and invasion and metastasis, as well as the induction of apoptosis in vitro 30, 129, 130 and in vivo [131] [132] [133] . In addition, on the basis of the new role of ILK in mitosis 103, 104 , the potential targeting of ILK as an anti-mitotic chemotherapeutic might provide a promising alternative to anti-mitotic chemotherapeutics because severe toxic side effects and drug resistance are likely to be avoided.
Regarding p140CAP and its potential role as a tumour suppressor, the generation of decoy proteins that could function as the intact protein, may have important potential therapeutic applications. Moreover, human breast cancer analysis shows that p140CAP expression is inversely correlated with the aggressiveness of malignancy, suggesting that p140CAP could be a new prognostic factor for the diagnosis of poorly aggressive breast tumours.
Structure-based design of inhibitors should also be developed to target specific domains of these adaptor proteins, particularly regions that contain tyrosine or serine residues, or regions that are involved in binding with specific signalling effectors, such as PI3K, SRC, FAK and AKT. So far, only the crystal structure of the p130CAS SH3 domain has been resolved 134 , enabling the search for competitors and specific inhibitors of the p130CAS-FAK interaction.
Conclusions
As discussed in this Review, the adaptor proteins of the Cas family, CRK, p140CAP and the IPP complex, are crucial mediators of strictly interdependent cellular functions, such as survival, proliferation and migration, which have a key role in transformation and tumour progression. High expression levels of the members of the Cas family, CRK and the IPP complex components mainly drive tumorigenesis by enhancing oncogene signalling, sustaining the ability of cells to grow in anchorageindependent conditions, and to migrate on and invade the ECM. Conversely, high levels of the p140CAP adaptor negatively regulate tumour phenotypes, such as cell motility and proliferation, thus p140CAP possesses tumour suppressive activities.
As the expression level of these adaptors is crucial for their functions in transformed cells, along with extensive immunohistochemistry studies of human cancers, a detailed screening of gene and chromosome abnormalities in specific cancer types should be undertaken. Moreover, a deep analysis of the mechanisms that control gene expression, such as promoter structure for transcriptional control, miRNA-based regulation of gene expression and epigenetic modifications, is needed for all of these genes. Identification of exogenous factors, such as growth factors, cytokines and chemokines, which are able to finely tune their expression, is also important. Interestingly, p130CAS and p140CAP function as opposing regulators of SRC activity in tumour cells, suggesting the existence of molecular mechanisms that regulate their expression levels, their interaction and the final outcome that is mediated by the pathway.
As an additional field of investigation, proteomic analysis could clarify the crucial post-translational modifications (such as the presence of phosphorylated residues) that can contribute to the activation of specific signalling pathways by recruiting signalling molecules. Silencing of these proteins in different cancer models has been shown to be effective in downregulating or enhancing tumour properties, thus emphasising the importance of these adaptor molecules not only as prognostic markers but also as potential therapeutic targets.
